$201 Million is the total value of Opaleye Management Inc.'s 44 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 55.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | BLUEPRINT MEDICINES | $35,191,000 | +42.6% | 880,000 | 0.0% | 17.51% | +20.4% | |
| AXGN | AXOGEN INC | $20,586,000 | +16.1% | 1,970,000 | 0.0% | 10.24% | -1.9% | |
| FGEN | FIBROGEN INC | $8,134,000 | +15.2% | 330,000 | 0.0% | 4.05% | -2.7% | |
| NVLNF | New | NOVELION THERAPEUTICS INC | $7,840,000 | – | 730,000 | +100.0% | 3.90% | – |
| CMRX | Buy | CHIMERIX INC | $7,751,000 | +44.0% | 1,215,000 | +3.8% | 3.86% | +21.7% |
| AGIO | AGIOS PHARMACEUTICALS | $7,592,000 | +39.9% | 130,000 | 0.0% | 3.78% | +18.2% | |
| CARA | Sell | CARA THERAPEUTICS | $7,080,000 | +60.4% | 385,000 | -18.9% | 3.52% | +35.5% |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $6,627,000 | +31.4% | 180,000 | +13.8% | 3.30% | +11.0% |
| IMMU | New | IMMUNOMEDICS INC | $6,211,000 | – | 960,000 | +100.0% | 3.09% | – |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $5,874,000 | +18.3% | 440,000 | +33.3% | 2.92% | -0.1% |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $5,871,000 | +214.3% | 340,000 | +100.0% | 2.92% | +165.4% |
| CDXS | CODEXIS INC | $5,616,000 | +4.3% | 1,170,000 | 0.0% | 2.80% | -11.9% | |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $5,605,000 | +101.3% | 1,180,000 | +1.7% | 2.79% | +70.1% |
| LOXO | Buy | LOXO ONCOLOGY | $5,470,000 | +36.3% | 130,000 | +4.0% | 2.72% | +15.1% |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $5,104,000 | +551.9% | 550,000 | +487.6% | 2.54% | +451.0% |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $5,075,000 | +5.4% | 290,000 | +1.8% | 2.53% | -11.0% |
| PRTA | Buy | PROTHENA CORP PLC | $4,859,000 | +19.7% | 87,100 | +5.6% | 2.42% | +1.1% |
| EGRX | EAGLE PHARMACEUTICALS INC | $4,147,000 | +4.5% | 50,000 | 0.0% | 2.06% | -11.7% | |
| IMMY | Buy | IMPRIMIS PHARMACEUTICALS INC | $3,588,000 | +99.3% | 860,500 | +19.5% | 1.79% | +68.3% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $3,198,000 | +79.0% | 45,000 | +28.6% | 1.59% | +51.2% |
| Buy | NEURODERM LTD | $3,186,000 | +84.1% | 120,000 | +4.3% | 1.59% | +55.5% | |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $3,080,000 | +2.2% | 100,000 | +11.1% | 1.53% | -13.7% |
| SGMO | Buy | SANGAMO BIOSCIENCES INC | $3,021,000 | +147.6% | 581,000 | +45.2% | 1.50% | +109.2% |
| PROTALIX BIOTHERAPEUTICS INC | $2,624,000 | +205.5% | 1,930,000 | 0.0% | 1.31% | +158.1% | ||
| EDGE | EDGE THERAPEUTICS INC | $2,550,000 | -27.1% | 280,000 | 0.0% | 1.27% | -38.5% | |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $2,475,000 | -55.0% | 500,000 | +1.0% | 1.23% | -62.0% |
| ZSAN | New | ZOSANO PHARMA CORP | $2,375,000 | – | 1,250,000 | +100.0% | 1.18% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $2,255,000 | – | 550,000 | +100.0% | 1.12% | – |
| WVE | New | WAVE LIFE SCIENCES LTD | $2,153,000 | – | 78,300 | +100.0% | 1.07% | – |
| GNMX | Sell | AEVI GENOMIC MEDICINE INC | $1,990,000 | -74.4% | 1,070,000 | -28.7% | 0.99% | -78.4% |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $1,959,000 | – | 50,000 | +100.0% | 0.98% | – |
| LBIO | Sell | LION BIOTECHNOLOGIES INC | $1,713,000 | -17.8% | 230,000 | -23.3% | 0.85% | -30.6% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $1,440,000 | -53.8% | 360,000 | -11.1% | 0.72% | -61.0% |
| AQXP | Sell | AQUINOX PHARMACEUTICALS INC | $1,418,000 | -72.3% | 85,000 | -72.6% | 0.71% | -76.6% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $1,375,000 | -29.1% | 275,000 | -31.2% | 0.68% | -40.2% |
| TNXP | New | TONIX PHARMACEUTICALS HOLDING | $1,097,000 | – | 235,000 | +100.0% | 0.55% | – |
| CDTX | New | CIDARA THERAPEUTICS INC | $955,000 | – | 122,500 | +100.0% | 0.48% | – |
| ALBO | New | ALBIREO PHARMA INC | $876,000 | – | 36,500 | +100.0% | 0.44% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $770,000 | – | 60,000 | +100.0% | 0.38% | – |
| CORI | Sell | CORIUM INTERNATIONAL INC | $677,000 | -56.1% | 162,000 | -57.4% | 0.34% | -62.9% |
| ARQL | New | ARQULE INC | $593,000 | – | 560,000 | +100.0% | 0.30% | – |
| SYRS | New | SYROS PHARMACEUTICALS INC | $400,000 | – | 25,149 | +100.0% | 0.20% | – |
| XOMA | New | XOMA CORP DEL | $287,000 | – | 40,400 | +100.0% | 0.14% | – |
| BLRX | BIOLINERX LTDsponsored adr | $240,000 | +4.3% | 250,000 | 0.0% | 0.12% | -12.5% | |
| AGRX | Exit | AGILE THERAPEUTICS INC | $0 | – | -15,000 | -100.0% | -0.05% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -110,000 | -100.0% | -0.37% | – | |
| AKAOQ | Exit | ACHAOGEN INC | $0 | – | -80,000 | -100.0% | -0.61% | – |
| WGBS | Exit | WAFERGEN BIO-SYSTEMS INC | $0 | – | -320,000 | -100.0% | -0.93% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -1.08% | – |
| CLSD | Exit | CLEARSIDE BIOMEDICAL INC | $0 | – | -270,000 | -100.0% | -1.42% | – |
| OMER | Exit | OMEROS CORP | $0 | – | -265,300 | -100.0% | -1.55% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -170,000 | -100.0% | -2.05% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -1,000,000 | -100.0% | -7.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.